Review

Mechanism of Ferroptosis: A Potential Target for Cardiovascular Diseases Treatment

Jie Ju¹, Ya-nan Song², Kun Wang¹*

¹Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, China.
²Medical College of Qingdao University, Qingdao, China.

[Received January 8, 2020; Revised March 20, 2020; Accepted March 23, 2020]

ABSTRACT: Ferroptosis is a form of programmed cell death caused by production of reactive oxygen species and disequilibrium of iron homeostasis. Many chemical compounds and clinical drugs induce ferroptosis in normal and cancer cells, while peroxidation inhibitors, iron chelators, and antioxidants can block ferroptosis. Glutathione peroxidase 4, ferroptosis suppressor protein 1, nuclear factor erythroid 2-related factor 2, and system Xc are the negative regulators of ferroptosis, whereas nicotinamide adenine dinucleotide phosphate oxidase, p53, mitochondria voltage-dependent anion channel, and cysteinyl-tRNA synthetase function as positive regulators. Ferroptosis plays important roles in pathogen infection and tumor immunology. Recent studies suggest that ferroptosis plays a vital role in the pathogenesis of cardiovascular diseases (CVDs), which seriously threaten human health. Potential therapies designed around ferroptosis may alter the pathological progression of CVDs. Therefore, we redacted an overview of the discovery of ferroptosis, its regulatory mechanisms, and its potential impact on CVDs treatment.

Key words: ferroptosis, reactive oxygen species, iron, cardiovascular diseases

1. Introduction

Cell death plays important roles throughout all life stages, both in the embryo development and in growth, maturation, and senescence processes; it is vital for various aspects of health, such as homeostasis, pathology, and other biological responses. Ferroptosis is a recently recognized form of cell death that has attracted considerable attention in explaining the molecular processes that control the demise of cells. The core of ferroptosis is the selenoenzyme glutathione peroxidase 4 (GPX4), which contains the rare amino acid selenocysteine at its active site, which catalyzes the reduction of polyunsaturated lipid hydroperoxides (LOOHs) species to non-toxic hydroxy lipid species, thus preventing uncontrolled peroxidation of polyunsaturated fatty acids (PUFAs) and PUFA-containing membrane phospholipids (Fig. 1) [1]: oxidized lipids disrupt the barrier function of biological membranes by forming hydrophilic pores. Normal levels of iron are essential for growth and proliferation. However, the interaction between LOOHs and excessive ferrous iron (Fe²⁺) generates reactive oxygen species (ROS) that amplify lipid peroxidation reactions and generate highly reactive products detrimental to DNA or proteins [2]. In summary, iron imbalance (Fig. 2) and ROS production (Fig. 3), mainly caused by lipid peroxidation, are the key hallmarks of ferroptosis.
Figure 1. GPX4 is a key modulator of ferroptosis. Ferroptosis is induced by class I inducers (e.g., Erastin, BSO) and class II inducers (e.g., RSL-3), which inhibit GPX4 activity indirectly or directly, respectively. GPX4 is an inhibitory protein of lipid ROS production that catalyzes the reduction of lipid hydroperoxides. BSO: buthionine sulfoximine; PEBP1: phosphatidylethanolamine-binding protein 1; 15LO: 15-lipoxygenases; Lyso-PE: lysophosphatidylethanolamine; HpETE-PE: hydroperoxy eicasotetraenoyl phosphatidylethanolamine; PUFA: polyunsaturated fatty acid; CoA: coenzyme A; PL: lysophosphatidylethanolamine; GSSG: oxidized glutathione; GSH: reduced glutathione; ACSL4: acyl-CoA synthetase long-chain family member 4; LPCAT3: lysophosphatidylcholine acyltransferase 3; LOOH: polyunsaturated fatty acid hydroperoxides; LOH: hydroxy lipid species; GPX4: glutathione peroxidase 4; NAC: N-acetyl-l-cysteine; ROS: reactive oxygen species; SLC7A11: solute carrier family 7 member 11; SLC3A2: solute carrier family 3 member 2.

The heart is one of the busiest organs and the hardest working muscle in the body. The role of the heart is to pump blood, thus supplying oxygen and nutrition to organs and tissues and removing the end products of metabolism [3]. Currently, cardiovascular diseases (CVDs) have become the world's leading killer being responsible for 40% of all deaths (41 million people per year), so they seriously impact on human health. The World Health Organization reported in 2014 that the mortality of cardiovascular diseases should be reduced by 25% [4]. Therefore, studying the pathogenesis of cardiovascular diseases, especially cardiopathy, and finding viable therapeutic targets are problems requiring a prompt solution.

Studies have revealed that iron homeostasis imbalance, oxidative stress, inflammatory response, energy metabolism disorder, and mitochondrial damage come into play in cardiovascular diseases. This paper will mainly describe the mechanism of ferroptosis and the research progress in cardiovascular diseases, providing new ideas for the treatment of cardiovascular diseases.

2. Discovery of ferroptosis

In 1959, Harry Eagle tried to detect which substance were essential for metabolism; he found that, out of 13 different amino acids, only cysteine deficiency inhibits the growth of human and mouse cells. Cells cultured in a cysteine-deficient medium show a distinct morphology, different from other amino acids deprivation [5]. In the following years, studies have confirmed that cysteine deficiency and glutathione synthesis inhibition are important causes of cell death [6-8]. Only recently they were officially recognized as important characteristics of ferroptosis [2, 7], while other studies have found that both iron chelators and lipophilic antioxidants prevent the occurrence of this kind of cell death.

By screening small molecule pools to identify compounds selectively lethal for cells expressing the mutant oncogene HRAS, the Stockwell Laboratory identified in 2003 a compound named "erastin" [9]. The direct target of erastin was identified as a Na+ independent cystine/glutamate antiporter called system Xc; their interaction would block cystine uptake and then induce ferroptosis [9]. Only in 2012, ferroptosis was named for the first time and described as a regulated cell death dependent on excessive iron, and was characterized by the excessive presence of ROS and redox active iron [10]. A second ferroptosis inducer, the diastereoisomer 1S,3R-RSL3 (RSL3), was identified as a GPX4 inhibitor. RSL3 covalently binds and inactivates GPX4 to induce intense and selective lethality in HRASV12-expressing BJelR-derived cell lines but not in wild-type HRAS cell lines [1, 2, 11].
3. **Morphology of ferroptosis**

Ferroptosis is mainly characterized morphologically by shrunken mitochondria, which are smaller than normal mitochondria and primarily exhibit increased membrane density as well as cristae degeneration and breakdown, with few other significant morphological changes before ferroptosis [12]. Ultrastructral analysis demonstrated that ferroptosis involves outer mitochondrial membrane rupture in immortal mouse embryonic fibroblasts (MEFs) [13]. In addition, the morphology of the nucleus remains unchanged, not showing chromatin condensation. On the contrary, margination, condensation, and fragmentation of chromatin are typical features of classical apoptosis [2]. Excessive accumulation of ROS causes membrane lipid peroxidation, which damages the barrier function of the cell membrane. In addition, generation of apoptotic bodies and plasma membrane blebbing are other features of apoptosis. Necroptosis involves cell swelling, rupture of the cell membrane, and formation of annexin V-positive membrane bubbles, which relies on the mixed lineage kinase domain-like pseudokinase activation and on the endosomal sorting complexes required for transport-III [14]. None of these processes are present during ferroptosis and therefore distinguish ferroptosis from the other two described forms of regulated cell death. Another form of regulated cell death is autophagy, which is characterized by de novo synthesis of double-membrane vesicles loaded with organelles such as mitochondria; successive fusion with a lysosome leads to their digestion. This representative morphology of autophagy is also not found during ferroptosis [15]. Ferroptosis is thus morphologically distinguishable from apoptosis, necroptosis, and autophagy; therefore, we compared the four different cell death patterns by four aspects, as shown in Table 1, and in the class pattern diagram shown of Fig. 4 [16-20].

3.1. **The ferroptosis pathway**

Iron metabolism disorder (Fig. 2) and ROS production (Fig. 3) are key events in the ferroptosis cascade[10, 21] and as such need to be examined singularly.

3.1.1 Iron metabolism disorder

Ferroptosis is mediated by intercellular excessive iron; when coupled with transferrin, extracellular ferric iron (Fe$^{3+}$) is imported into cells through the membrane protein transferrin receptor 1 (TIR1). Within the cell, Fe$^{3+}$ is located in the endosome and is then reduced to Fe$^{2+}$ by the metalloreductase STEAP family member 3 [22]. Fe$^{2+}$ is stored by ferritin, which can be degraded by NCOA4-mediated ferritinophagy. In addition, Hmox1 catalyzes heme degradation and releases iron. Excess iron induces ROS production by the Fenton reaction to initiate ferroptosis. NRF2: erythroid 2-related factor 2; Hmox1: heme oxygenase-1; ROS: reactive oxygen species; DFO: deferoxamine; DMT1: divalent metal transporter 1; STEAP3: STEAP family member 3; TfR1: transferrin receptor 1; NCOA4: nuclear receptor coactivator 4; NRF2: erythroid 2-related factor 2; Hmox1: heme oxygenase-1; ROS: reactive oxygen species; DFO: deferoxamine; DMT1: divalent metal transporter 1; STEAP3: STEAP family member 3; TIR1: transferrin receptor 1.
released into the cytoplasm iron pool through the mediation of the divalent metal transporter 1 [23]. Cellular iron can be oxidized from Fe$^{2+}$ to Fe$^{3+}$ and exported by ferroportin to maintain normal iron levels. Alternatively, excess iron is stored in ferritin and forms redox-inactive ferritin heteropolymers to preserve tissues and cells against ferroptosis-mediated injury. In particular circumstances, the nuclear receptor coactivator 4 (NCOA4)-mediated ferritin degradation increases iron levels to induce ferroptosis [12, 24, 25]. When treating HRAS$^V12$ mutant fibrosarcoma cells with erastin, TiR1 mRNA and protein levels gradually increase, but the expression level of both ferritin heavy chain 1 (FTH1) and ferritin light chain decreases. This suggests that increased iron uptake via TiR1 upregulation and reduced iron storage by FTH1 and ferritin light chain downregulation contribute to iron overload during ferroptosis [11]. Upregulation of heme oxygenase-1 (Hmox1) promotes heme degradation and iron release in mouse heart tissue upon administration of doxorubicin (DOX) (Fig. 2) [26]. In addition, heat shock protein family B member 1 phosphorylation mediated by protein kinase C negatively regulates iron-mediated lipid ROS production in erastin-treated HeLa cells [27]. Mutation of some iron metabolism-related genes such as homeostatic iron regulator, hemojuvelin, causes hemochromatosis, an iron-overloading disease. Both hemojuvelin and hepatocyte specific Smad4 gene knockout mice develop high iron overload, which leads to hepatic ferroptosis. On the contrary, homeostatic iron regulator knockout mice develop only mild iron overload and do not show hepatic ferroptosis; furthermore, their liver damage is recovered by ferrostatin-1 [28].

NCOA4 maintains intracellular and systemic iron homeostasis by mediating the selective autophagic degradation of ferritin (process known as ferritinophagy). Inhibition of ferritinophagy or knockdown of NCOA4 inhibit the accumulation of reactive iron and ROS as well as the eventual development of ferroptosis [29]. NCOA4 interacts with HERC2 ubiquitin E3 ligase and mediates ubiquitin-dependent proteasome degradation when cellular iron levels are high [30]. NCOA4 combined with iron-loaded ferritin is delivered into the pre-autophagosome structure. Ferritin is degraded in the lysosome after fusion with the autophagosome. The iron is thus released into the lysosome by ferritin and then transferred in the cytoplasm. These free iron ions can participate in the biological synthesis of heme and in other physiological processes (Fig. 2) [31].

Figure 3. ROS production mediated by diverse signaling pathways. LOX, VDAC2/3, TCA, PPP, glutaminolysis, and lipid synthesis pathways promote ROS production. Antioxidative genes regulated by NRF2 and reductive GSH inhibit ROS production. CS: citrate synthase; ACSF2: acyl-CoA synthetase family member 2; NOX: nicotinamidase adenine dinucleotide phosphate oxidase; NADPH: nicotinamidase adenine dinucleotide phosphate; PPP: pentose phosphate pathway; GLUD1: glutamate dehydrogenase 1; AOA: amino-oxyacetate; α-KG: α-ketoglutarate; LOX: lipoxygenases; GPX4: lipoxygenases; ROS: reactive oxygen species; GSH: reduced glutathione; NRF2: erythroid 2-related factor 2; VDAC: mitochondrial voltage-dependent anion channel; Met: methionine; CARS: cysteinyl-tRNA synthetase; LPCAT3: lysophosphatidylcholine acyltransferase 3; ACSL4: acyl-CoA synthetase long-chain family member 4; 6-AN: 6-aminonicotinamide; PUFA: polyunsaturated fatty acid.
Table 1. Characteristics of different forms of cell death.

| Type       | Morphological features                                                                 | Biochemical features                                                                 | Activation manner                                                                 | Regulated genes                                                                 |
|------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Ferroptosis| Small mitochondria with increased mitochondrial membrane densities; Outer mitochondrial membrane rupture and normal nucleus | iron metabolism and ROS production                                                  | Erastin; Sorafenib; RSL3                                                          | Positive regulation: VDAC2/3; RAS; NOX; TIR1; p53; CARS; ACSL4; Hmx1; NCOA4    |
|            |                                                                                       |                                                                                      |                                                                                   | Negative regulation: GPX4; NRF2; HSPB1; SLC7A11; FSP1; PEBP1; 15LO               |
| Apoptosis  | Plasma membrane blebbing without rupture; chromatin condensation and nuclear fragmentation; formation of apoptotic bodies | Caspase activation; DNA fragment; PS exposure                                       | Physiological or pathological conditions                                           | Positive regulation: Caspase; Cytc; BH3 family; Bax family; p53                |
|            |                                                                                       |                                                                                      |                                                                                   | Negative regulation: Bel-2 family                                               |
| Necroptosis| Rupture of plasma membrane; cytoplasmic swelling; organelles swelling; moderate chromatin condensation | RIPK1, RIPK3 and MLKL phosphorylation; ROS production; DAMPs release                | TNF-α plus pan-Caspase inhibitor co-treatment; HSV-1 infection                    | Positive regulation: RIPK1; RIPK3; MLKL                                       |
|            |                                                                                       |                                                                                        |                                                                                   | Negative regulation: Flotillin; syntenin-1                                       |
| Autophagy  | Accumulation of double-membraned autophagic vesicle                                      | LC3-I to LC3-II conversion; p62 degradation                                          | Nutritional deficiencies; oxidative stress                                       | Positive regulation: ATG5; ATG7; Beclin 1                                       |
|            |                                                                                       |                                                                                        |                                                                                   | Negative regulation: mTOR                                                       |

3.1.2 ROS production

One of the main inductors of ferroptosis is ROS presence, which is caused by nicotinamide adenine dinucleotide phosphate oxidase (NOX) action, transsulfuration pathway activities, and lipid or PUFA peroxidation. In addition, many proteins negatively regulate ROS production, such as GPX4 (Fig. 3). Treatment with erastin leads to the inactivation of GPX4, inducing mitochondrial dysfunction, an unbalance of cellular redox homeostasis, and generation of lipid peroxides, which altogether unleash ferroptosis [32, 33].

Mitochondrial fatty acid metabolism is important to trigger or moderate ferroptosis induced by cysteine deprivation. The main functions of mitochondria are the tricarboxylic acid (TCA) cycle and electron transport required for lipid ROS generation, which trigger ferroptosis. However, ferroptosis induced by GPX4 depletion is independent of mitochondrial functions [34]. The citrate synthase of the TCA cycle and the acyl-CoA synthetase family member 2 of the fatty acid synthesis pathway are key components of fatty acid metabolism: silencing acyl-CoA synthetase family member 2 and citrate synthase specifically attenuates erastin-induced ferroptosis [10].

Nicotinamide adenine dinucleotide phosphate is the main product of the pentose phosphate (PPP) pathway, which participates in lipid synthesis by providing reducing power. NOX generates ROS in various tissues as part of its normal physiological functions [35]; NOX inhibitors D1, GKT137831, and PPP pathway inhibitor 6-aminonicotinamide thus inhibit ferroptosis by attenuating ROS production [36].

Glutamate is an important molecule that induces ferroptosis, which cannot be commenced by cells without this amino acid. The destiny of glutamate is to be transformed into α-ketoglutarate by glutamate dehydrogenase 1-mediated deamination, or into a lipid by transaminase-mediated transamination. Treatment with the transaminase inhibitor amino-oxyacetate or by knockdown of glutamic-oxaloacetic transaminase 1 inhibits ferroptosis. Moreover, TCA cycle products of glucose also convert to lipids and participate in ROS production [10].

ROS react with PUFAs in lipid membranes and induce lipid peroxidation. Acyl-CoA synthetase long-chain family member 4 (ACSL4) is essential for ferroptosis. Specifically, GPX4 and ACSL4 double-knockout cells resist ferroptosis [37]. Nine genes involved in ferroptosis were identified in KMB7 cells by massive insertional mutagenesis; those included mediators of ACSL4 and lysophosphatidylcholine acyltransferase 3 (LPCAT3) (Fig. 1), but only a little protective effect was observed in LPCAT3 knockout Pfa1 cells [37, 38]. This indicates that ACSL4 plays a more widespread role in ferroptosis and that the function of LPCAT3 is restricted to certain cellular subtypes.

Arachidonic acid and linolenic acid are substrates of lipoxygenases (LOX). The LOX family plays a vital role in the synthesis of LOOHs, which participates in various pathologies including neurodegeneration, ischemia-reperfusion injury (IRI), and infection. LOX-overexpressing cells are inclined to lipid peroxidation and ROS production, which sensitize to ferroptosis induced by erastin or RSL3, in spite of slightly different extents [39].
Aging and Disease • Volume 12, Number 1, February 2021

Targeting ferroptosis to treat cardiovascular diseases

Table 2: Genes involved in ferroptosis regulation.

| Genes | Name | Function | Effect |
|-------|------|----------|--------|
| NOX   | NADPH oxidase activator | Produces ROS which participates in host defense, hormone biosynthesis, oxygen sensing and signal transduction. | Regulate ferroptosis Positively |
| TTR1  | Transferrin receptor protein 1 | Mediates iron uptake | Regulate ferroptosis Positively |
| ACSL4 | Acyl-CoA synthetase long-chain family member 4 | Converts free fatty acids into fatty acyl CoA | Regulate ferroptosis Positively |
| p53   | Cellular tumor antigen p53 | Inhibits SLC7A11 expression | Regulate ferroptosis Positively |
| CARS  | Cysteiny-l-tRNA synthetase | Participate in trans-sulfuration pathway and synthesis of GSH | Regulate ferroptosis Positively |
| MAPK  | Mitogen-activated protein kinase 1 | Mediates cell growth, adhesion, survival and differentiation | Regulate ferroptosis Positively |
| NCOA4 | Nuclear receptor coactivator 4 | Mediates iron metabolism | Regulate ferroptosis positively |
| 15LO  | 15-lipoxygenases | Catalyzes the formation of pro-ferroptotic 15-OOH-AA (HpETE) | Regulate ferroptosis positively |
| PEBP1 | Phosphatidylethanolamine-binding protein 1 | Inhibits the Raf/MEK/ERK cascade | Regulate ferroptosis positively |
| Hmox1 | Heme oxygenase 1 | Catalyzes degradation of heme | Regulate ferroptosis positively |
| GPX4  | Glutathione peroxidase 4 | Reduces phospholipid hydroperoxide | Regulate ferroptosis negatively |
| SLC7A11 | Cystine/glutamate antiporter solute carrier family 7 member 11 | Mediates cystine uptake and glutamate release | Regulate ferroptosis negatively |
| HSPB1 | Heat shock protein beta-1 | HSPB1 phosphorylation is negative regulated iron-mediated lipid ROS production | Regulate ferroptosis negatively |
| NRF2  | Nuclear factor erythroid 2-related factor 2 | Binds to ARE elements in the promoter regions of target genes | Regulate ferroptosis negatively |
| FSP1  | Ferroptosis suppressor protein | Reduces phospholipid hydroperoxide | Regulate ferroptosis negatively |

3.2. Ferroptosis regulation

The ferroptosis process involves multiple proteins such as p53, small G-protein Ras (RAS), VDAC2/3, mitogen-activated protein kinase (MAPK), NCOA4, NOX, cysteiny-l-tRNA synthetase (CARS), and others. Also, some negative regulators genes of ferroptosis exist, such as GPX4, system Xc- and erythroid 2-related factor 2 (NRF2), which protect cells against ferroptosis; knockout of these genes induces ferroptosis in vitro, as shown in Table 2.

3.2.1 Positive regulator

VDAC is a mitochondrial voltage-dependent, anion selective channel that facilitates transmembrane transport of ions and metabolites. Erastin is a VDAC-binding small molecule that possibly influences ion selectivity and allows cationic species into mitochondria selectively, which is lethal to some cancer cells [33]. Erastin-induced ferroptosis stops the interaction between VDAC and tubulin, thereby enhancing mitochondrial metabolism and limiting aerobic glycolysis in HepG2 cells [33, 40].

HRAS, NRAS, and KRAS belong to the small GTPase superfamily, which are mutated in approximately 30% of all cancers [41]. Erastin is lethal to HRAS mutant BJelR cells, NRAS mutant HT-1080 cells, and KRAS-mutant Calu-1 cells [11]. Nevertheless, lymphocyte T cells, synchronized kidney tubular cells, and mouse embryonic fibroblast (MEF) cells are sensitive to erastin, independently of the RAS [42-44].

The transcription factor p53 is a crucial protein in multicellular organisms; the inactivation of the p53 tumor suppression pathway is inclined to transform most human tissue cells to cancer cells [45]. Recent studies have found that p53 directly binds to the flanking region of the human solute carrier family 7-member 11 (SLC7A11) gene, thus severely reducing SLC7A11 expression and activating ferroptosis [44]. Notably, p53^{3KR}, an acetylation-defective p53 mutant that fails to induce cell cycle arrest, apoptosis, and senescence, still exhibits tumor suppression by binding the promoter of the SLC7A11 gene to active ferroptosis (Fig. 1) [44]. SLC7A11 mRNA expression is suppressed in p53^{3KR/3KR}Mdm2+/-embryos, which induces ferroptosis to a large extent. P53^{3KR/3KR}Mdm2+/-embryos treated with ferrostatin-1 showed clear organogenesis after day E14.5. Overall, p53-mediated ferroptosis plays an important role in the defective embryonic development of p53^{3KR/3KR}Mdm2+/- mice [44].

The mitochondrial electron transport chain is a source of ROS in erastin-induced ferroptosis. NOX1, 2, 3, 4, and 5, and dual oxidase 1 and 2 are upregulated in
several RAS mutant tumors [46]. Erastin-induced ferroptosis is strongly suppressed in human lung cancer Calu-1 cells by the canonical NOX inhibitor, the NOX1/4-specific inhibitor GKT137831, and by the PPP pathway inhibitor 6-AN, but also by shRNA-mediated silencing of two PPP enzymes, glucose-6-phosphate dehydrogenase and phosphoglycerate dehydrogenase [10, 36].

CARS (cysteinyl-tRNA synthetase) is the rate-limiting enzyme for cysteinyl-tRNA synthesis. Knockdown of CARS promotes transsulfuration pathway activation and serine biosynthesis, thus inhibiting erasin-induced cell death by preventing lipid ROS production, although it has no influence on iron homeostasis [47]. Moreover, repression of the transsulfuration pathway resensitizes cells to erasin. However, CARS knockdown cannot inhibit RSL3-induced lethality. The reason for this phenomenon is that RSL3 directly inhibits GPX4 biological activity; the inhibition is not avoided even increasing the levels of oxidized glutathione, reduced glutathione (GSH), or cysteine [47].

The MAPK family includes c-JUN N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38. The ERK inhibitor, but not p38 or JNK inhibitors, inhibits the erastin-induced signal transducer and the activator of transcription 3 phosphorylation and ferroptosis in KRAS mutated PANC1 and CFPAC1 cells [48]. Knockdown of ERK1/2 and of upstream regulator MAPK kinase1/2 restrains the signal transducer and activator of transcription 3 phosphorylation and enhances resistance to erastin in PANC1 cells [48]. JNK and p38 inhibitors attenuate erastin-induced ferroptosis in human promyelocytic leukemia HL-60 cells. Together, these findings suggest that MAPK molecules involved in ferroptosis are cell-specific.

Phosphatidylethanolamine-binding protein 1 (PEBP1) is a small scaffolding protein that binds to Raf1 to repress its cascade reaction. Phosphorylated PEBP1 also binds to 15-lipoxygenases (15LO), which catalyzes the formation of pro-ferroptotic 15-OOH-arachidonic acid (HpETE) and esterifies phosphatidyl ethanolamine with HpETE to generate HpETE PE [49]. The 15LO/PEBP1 complex stimulates PE oxygenation and forms 15-HpETE-PEs to induce ferroptosis. The disruption interactions between PEBP1 and Raf1 kinase liberates the protein and makes it available for binding.

**Figure 4. Distinctive forms of programmed cell death and their morphological characteristics.** Ferroptosis does not result in chromatin condensation, loss of plasma membrane integrity, or the formation of double membrane-layered autophagosomes. The most evident morphology of ferroptosis is the smaller than normal mitochondria, with increased membrane density and no cristae. In addition, the metabolic disturbance of iron and excess ROS production are the main characteristics of ferroptosis. Apoptosis is characterized by cell shrinkage, membrane blebbing, chromatin condensation, and formation of apoptotic bodies, which are then devoured by neighboring macrophages. Necroptosis occurs as a consequence of irreparable cell damage and is characterized by cell swelling and plasma membrane rupture. Cellular contents that are released outside the cell cause an inflammatory response in the surrounding tissue. Autophagy is characterized by the formation of double-membrane vesicles called autophagosomes. The fusion of autophagosomes and lysosomes forms autolysosomes, and their inclusions are then digested by hydrolases. ROS: reactive oxygen species; DAMPs: damage-associated molecular patterns.
Aging and Disease reported that ferroptosis suppressor protein 1 (FSP1) is an upstream of GPX4, such as GSH depletion and cysteine uptake. BSO inhibits biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less potent than the system Xc inhibitor erasin or GPX4 inhibitor RSL3. The reason why BSO only mildly induces ferroptosis is that BSO inhibits the peroxidase activity of GPX4 without inhibiting biosynthesis of GSH in the liver and other peripheral organs. BSO inhibits GPX4 through GSH depletion, which results in ferroptosis. Although BSO has the ability to induce ferroptosis, it is less poten
Table 3: Ferroptosis inducers and inhibitors.

| Reagents                  | Target       | Function                                      | Effect                          |
|---------------------------|--------------|-----------------------------------------------|---------------------------------|
| erastin                   | System Xc    | Inhibits cystine import, causes GSH depletion | Induces ferroptosis             |
| glutamate                 | System Xc    | High concentration glutamine inhibits cystine uptake and GSH synthesis | Induces ferroptosis             |
| sorafenib                 | System Xc    | Blocks system Xc activity and GSH synthesis   | Induces ferroptosis             |
| sulfasalazine             | System Xc    | Low potency than erastin to induce ferroptosis | Induces ferroptosis             |
| artemisinin               | Unknown      | Promotes iron-related genes expression        | Induces ferroptosis             |
| DPI2                      | GSH          | Depletes GSH                                  | Induces ferroptosis             |
| RSL3                      | GPX4         | Covalently binds to the GPX4 and promotes accumulation of lipid hydroperoxides | Induces ferroptosis             |
| DPI7,10,12,13,17,18,19    | GPX4         | Covalently binds to the GPX4 and promotes accumulation of lipid hydroperoxides | Induces ferroptosis             |
| Lanperisone               | System Xc    | Promotes ROS production                       | Induces ferroptosis             |
| Buthionine sulfoximine    | GSH          | Inhibits γ-glutamyl cysteine synthetase and GSH synthesis | Induces ferroptosis             |
| Ferrostatin-1             | ROS          | Prevents ROS production from lipid peroxidation | Inhibits ferroptosis           |
| Liproxstatin-1            | ROS          | Prevents ROS production from lipid peroxidation | Inhibits ferroptosis           |
| N-acetyl-L-cysteine       | ROS          | Scavenges cellular ROS                        | Inhibits ferroptosis           |
| Vitamin E                 | 5-Lipoxygenase | Maintains cellular redox homeostasis         | Inhibits ferroptosis           |
| Zileuton                  | 5-Lipoxygenase | Maintains cellular redox homeostasis         | Inhibits ferroptosis           |
| SRS 11-92, SRS 16-86      | ROS          | Prevents ROS production from lipid peroxidation | Inhibits ferroptosis           |
| Deferoxamine              | Fe²⁺         | Chelates excess iron                          | Inhibits ferroptosis           |
| XJB-5-131, JP4-039        | ROS          | Scavenges cellular ROS                        | Inhibits ferroptosis           |
| Mitoquinone               | ROS          | Inhibits mitochondrial superoxide generation  | Inhibits ferroptosis           |

Lanperisone induces ferroptosis by promoting ROS production mediated by the RAS/Raf/MEK/ERK signaling pathway to kill KRAS-mutant mouse embryonic fibroblasts. However, lanperisone shows lower efficacy than erastin against KRAS-driven lung tumor growth [57].

Sulfasalazine is approved by the Food and Drug Administration for the treatment of chronic inflammation. Sulfasalazine inhibits SCL7A11 activity and induces ferroptosis in glioma cells at higher concentrations (>200μM) [58].

Sorafenib is a multikinase inhibitor approved in clinical settings as an anticancer drug for the treatment of hepatic carcinoma [59]. Sorafenib inhibits tumor cell proliferation by blocking the RAS/Raf/MEK/ERK signaling pathway, and attenuates tumor angiogenesis by blocking the vascular endothelial growth factor receptor 2 pathway and platelet-derived growth factor receptors [60]. Sorafenib induces ferroptosis similarly to erastin. The ferroptotic effect of sorafenib on hepatic carcinoma cells depends on the blockage of GSH synthesis rather than its inhibitory Raf signal pathway [60].

Artemisinin and its derivatives kill plasmodia parasites and cancer cells, depending on the presence of ferric iron ions. Artemisinin generates ROS and leads to oxidative stress in cancer cells, which contributes to cell death [61]. Artesunate is an artemisinin derivative that specifically induces ferroptosis in KRAS mutation pancreatic ductal adenocarcinoma cells but not in human pancreatic ductal epithelial cells.

All members of the DPI family can induce ferroptosis by inhibiting GPX4 activity. DPI2 follows the same mechanism as erastin to induce ferroptosis. BJeLR cells treated with DPI7, DPI10, DPI12, DPI13, DPI17, DPI18, and DPI19 cannot reduce phosphatidylycholine hydroperoxide, a specific substrate of GPX4, which indicates that these DPI family members directly inhibit GPX4 function [1].

3.4. Ferroptosis inhibitors

Ferroptosis induced by RSL3 or erastin can be blocked by most antioxidants (e.g., ferrostatin-1, liproxstatin-1, vitamin E), iron chelation (e.g., deferoxamine), and ROS scavengers (e.g., N-acetyl-L-cysteine, XJB-5-131, JP4-039, and Mitoquinone), as shown in Table 3 [1, 13, 21, 62-65].

Ferrostatin-1 and liproxstatin-1 attenuate the accumulation of lipid ROS by trapping radical antioxidants, but do not inhibit LOX activity and thus do not limit ferroptosis [63, 66]. Lipid cytomembrane constraining of ferrostatin-1 by its N-cyclohexyl moiety.
suppresses ferroptosis. The antioxidants vitamin E and α-tocotrienol are shown to inhibit ferroptosis via LOX suppression [67]. Zileuton, a LOX inhibitor, protects neurocytes from glutamate-induced oxidative injury by inhibiting ferroptosis [68].

Based on the chemical structure of ferrostatin-1, scientists have exploited the second-generation ferroptosis inhibitor SRS 11-92 and third-generation inhibitor SRS 16–86, which have higher potential for the treatment of renal IRI and promote functional recovery in contusion spinal cord injury [42, 69]. Liproxstatin-1 prevents ROS accumulation in GPX4-/- cells; this treatment also protects primary human renal proximal tubule epithelial cells from RSL3-induced cell death [10, 13]. Furthermore, daily intraperitoneal liproxstatin-1 administration remarkably extends survival compared with the vehicle-treated group mice and prevents tissue injury induced by renal IRI [13].

Superfluous iron produces ROS mediated by the Fenton reaction, which contributes to ferroptosis (Fig. 2). Thus, intracellular iron can be chelated by deferoxamine, which protects cells against ferroptosis induced by erastin treatment or GPX4 null-triggered cell death [22].

ROS is a characteristic component of ferroptosis and is mainly produced by lipid peroxidation. Supplementation with the ROS scavenger N-acetyl-l-cysteine significantly inhibits erastin-induced ferroptosis [1]. Recently, some ROS scavengers XIB-5-131 and JP4-039 were synthesized to inhibit ferroptosis by diminishing lipid ROS production [65]. Mitoquinone is a mitochondria-targeted ROS scavenger, which is sufficient against ferroptosis induced by erastin or GPX4 knockout, since during ferroptosis more lipid ROS are produced than mitochondria ROS [13].

3.5. Detection of ferroptosis

Cell viability: Cell Counting Kit-8 and trypan blue assays are well-known methods to detect cell viability and are also appropriate for detecting ferroptosis. Alamar Blue and calcein acetoxymethyl ester viability assays have also been reported to correctly estimate ferroptosis [10].

Iron level: Phen Green SK probes are green permeability dyes used to detect intracellular iron in living cells by flow cytometry or confocal microscopy. The green fluorescence of Phen Green SK probes binding to cellular iron is attenuated in ferroptotic cells upon treatment with erastin [53]. Transferrin-bound iron is released at an acidic pH and reduced from ferric to ferrous ions. These ions react with ferrozine to form a violet-colored complex, which is measured spectrophotometrically at 560nm. The absorbance measured at this wavelength is proportional to the serum iron concentration. According to this principle, serum non-heme iron levels are measured using the Iron/TIBC Reagent designed by Pointe Scientific, Inc. [26]. The tissue non-heme iron levels are measured using the chromogen method [70].

ROS level: ROS production can be assayed by flow cytometry using the fluorescent probes C11-BODIPY and 2’,7’-dichlorofluorescein diacetate (DCFH-DA) [10]. The C11-BODIPY probe shifts the fluorescence from red to green in HT-1080 cells upon treatment with erastin. DCFH-DA has no fluorescence and can be hydrolyzed by intracellular esterase to produce DCFH. Intracellular ROS oxidizes non-fluorescent DCFH into green fluorescent DCF and are thus monitored by fluorescence microscopy or flow cytometry. Moreover, dihydrorhodamine enters the cytoplasm and is oxidized into 1,2,3-rhodamine, which can emit fluorescence after entering the cell. The corresponding FITC fluorescence intensity can be detected by flow cytometry after a certain period of accumulation, to detect ROS levels [71]. 4-Hydroxynonenal and malondialdehyde (MDA) are endogenous products derived from the peroxidation of ω-6 PUFAs, which can be used to detect ROS production. MDA and 4-hydroxynonenal in cells, tissues, and serum can be detected using the thiobarbituric acid colorimetric method and enzyme linked immunosorbent assay [26, 72].

Biomarker protein: Prostaglandin-endoperoxide synthase-2 (PTGS2), known as cyclooxygenase (COX-2), is upregulated in BJELR cells upon treatment with either erastin or RSL3. Knockdown of GPX4 also increases PTGS2 mRNA abundance. However, ferroptosis induced by erastin or RSL3 is not affected by COX-2 inhibitor indomethacin treatment, suggesting that PTGS2 does not regulate ferroptosis, but that the increase of PTGS2 could be a marker for ferroptosis [1]. COX-2, ACSL4, and NOX1 are upregulated during ferroptosis, and the expression of GPX4, FTH1, and SLC7A11 proteins is downregulated in ferroptotic cells, thus constituting potential marker proteins for ferroptosis [1, 10, 37, 44, 73]. Furthermore, metallothionein-1 has been identified as a potential biomarker, since it reflects the redox metabolism of sorafenib-induced ferroptosis in cancer cells [74].

3.6. Ferroptosis and cardiovascular diseases

Cardiovascular diseases are caused by vascular abnormalities based on atherosclerosis. Hypertension, dyslipidemia, diabetes, and other diseases increase the risk of cardiovascular diseases. There is no direct evidence that ferroptosis is involved in the pathogenesis of atherosclerosis, but relevant studies show that the formation of arterial plaques is related to lipid peroxidation of vascular endothelial cells, iron deposition,
lipid deposition, and genesis of micrangium after injury. Studies have revealed that GPX4 overexpression alleviates atherosclerotic lesions in the aortic sinus and aortic tree of ApoE-deficient mice [75]. Furthermore, GPX4 knockdown causes an increase in the levels of lipid peroxidation and induces cytotoxicity. On the other hand, antioxidant vitamin E mitigates lipid peroxidation and cytotoxicity, and delays cell death induced by GPX4 knockdown [75].

Platelet aggregation and thrombus formation are the main causes of myocardial infarction. Markus Wortmann et al. found that one possible reason for the thromboembolic diseases in tamoxifen-inducible endothelial-specific GPX4 knockout (GPX4<i>IECKO</i>) mice might be endothelial cell death, because dying endothelial cells are known to be procoagulant. GPX4<i>IECKO</i> mice display an elevated resting arteriolar vessel tone, which indicates a higher mean arterial blood pressure. MDA, a ferroptosis marker, is elevated in the serum of vitamin E-depleted GPX4<i>IECKO</i> mice. The deficiency of GPX4 combined with deprivation of vitamin E decreases endothelial vasodilators and functionality, which brings about thromboembolic events [76]. It is a remarkable fact that supplementation of vitamin E lowers the risk of venous thromboembolism, especially in women with an anamnesis of venous thromboembolism or family history [77].

The initial manifestation of cardiovascular diseases is a vascular abnormality. Heart failure is the late stage of pathogenesis, and the death of differentiated cardiomyocytes is one of the root causes of cardiovascular diseases. For a long time, caspase-dependent apoptosis was considered the main form of myocardial cell death, but recently ferroptosis has been shown to play an important role in the development of cardiovascular diseases.

Myocardial infarction causes myocardial cell death, ventricular remodeling, and heart failure. The mechanistic target of rapamycin (mTOR) promotes the expression of TIR1 and ferroportin and alters cellular iron flux to protect the heart against pathological stimuli such as ischemia [73, 78]. ROS production is significantly lower in mTOR transgenic cardiomyocytes than in control cardiomyocytes. Overexpression of mTOR regulates ROS and iron metabolism to inhibit ferroptosis in cardiomyocytes, while mTOR deficiency promotes iron-induced ferroptosis [78].

Heart ischemia and reperfusion induce subsequent cardiac myocyte death, a more common form of damage to the heart muscle. Recent studies have demonstrated that deferoxamine alleviates myocardial IRI and erastin-
induced ferroptosis in cardiomyocytes. Rat hearts subjected to IRI or myocardial hypoxia/reoxygenation showed an increase of TIR1 expression and intracellular iron content, accompanied by upregulation of the ferroptosis marker protein ACSL4; this indicates that ferroptosis may participate in IRI or hypoxia/reoxygenation myocardial cell death [25]. Heart transplantation is accompanied by ischemia and reperfusion injury, which causes significant initiation of inflammatory responses. Neutrophils that are recruited to the site of sterile inflammation are triggered by damage-associated molecular patterns generated by ferroptotic cardiomyocytes and induce graft dysfunction [79]. Ferroptosis encourages neutrophils to adhere to damaged blood vessel through a TLR4/TRIF/type I IFN signaling pathway that induces inflammatory responses. Ferrostatin-1 reduces levels of ferroptotic hydroperoxyarachidonoyl-phosphatidylethanolamine, alleviates cardiomyocyte cell death, reduces left ventricle remodeling and infarcted area, improves left ventricular systolic function, and blocks neutrophil recruitment following heart transplantation (Fig. 5A). Inhibition of ferroptosis protects the heart after heart transplantation [80].

Heart failure is a syndrome in which the pumping function of the heart is impaired, and the cardiac output cannot meet the basic metabolic needs of the whole body. One of the most significant pathophysiological features is cardiomyocyte death [81]. Puerarin, an antioxidant reagent, alleviates heart failure in rats with aortic banding and exhibits cardioprotective functions in clinical trials. A recent study revealed that puerarin reduces iron content and increases ROS elimination in the rat heart failure disease model [82]. DOX is a second-generation anthracycline and has highly effective broad-spectrum anti-tumor activity for the treatment of the malignancy of the blood system and of solid tumors. However, dose-dependent heart failure limits its clinical application. Single treatment based on ferrostatin-1 or on the iron chelator dexrazoxane defends cardiomyocytes against heart failure. Moreover, DOX-induced mortality is reduced in receptor interacting serine/threonine kinase 3 knockout (Ripk3−/−) mice compared with wild-type littermates, while ferrostatin-1 treatment further extends the survival of DOX-induced cardiomyopathy compared with the vehicle-treated group in Ripk3−/− mice [26]. A low iron diet significantly raises the survival rate and limits severe heart damage under the condition of in vivo DOX-induced heart failure. The expression of Hmox1 was upregulated in DOX-treated murine hearts compared with the vehicle-treated group, as revealed by RNA-sequencing. The Kelch-like ECH-associated protein 1 (Keap1)/NRF2 pathway is activated through oxidative stress in an animal model of DOX-induced cardiomyopathy and myocardial IRI. The transcriptional factor NRF2 binds to the upstream promoter region of the antioxidant response element to enhance the expression of several antioxidative genes, including Hmox1. DOX administration induces ferroptosis caused by upregulation of the NRF2/Hmox1 pathway, acceleration of heme degradation, and release of free iron from heme groups (Fig. 5B) [26]. Significant accumulation of free iron and lipid peroxides is more easily observed in mitochondria than in the cytosol of DOX-treated animal hearts [26]. MitoTEMPO, a mitochondria-targeted superoxide dismutase, limits DOX cardiomyopathy, which indicates that oxidative damage to mitochondria is a major mechanism in ferroptosis-induced heart damage [83].

Cardiomyopathy is a progressive heart disorder accompanied by cardiomyocyte death. Previous studies have shown that patients with thalassemia have an increased risk of cardiomyopathy compared to the normal population, which may be related to the increased iron content in these patients caused by multiple blood transfusions. When the iron storage capacity of the liver is exceeded, iron penetrates the heart, leading to heart failure and rhythm disorders. During this process, iron overload causes cell death, while iron chelators prevent iron overload-induced cell death in cardiomyocytes [84]. Recent studies have shown that hemodynamic dysfunctions associated with iron status and protein and lipid heart oxidative stress are more common in the heart of aged rabbits than in adult rabbits [85].

4. Conclusions and Perspectives

Substantial steps have been made in the exploration of the ferroptosis mechanism over the past few years. The main causes of ferroptosis are iron metabolism disorder and ROS production. The homeostasis of PUFAs and iron is important for vital processes such as individual growth and development. When such homeostasis falters, GPX4 is inactivated and cytomembrane PUFAs are peroxidized by ROS, thus disrupting membrane functionality and inducing ferroptosis [1]. One of the most prominent features of ferroptosis is PUFA or phospholipid peroxidation, which is indicated by COX-2 or MDA upregulation [26]. The accumulation of excessive iron is another feature of ferroptosis [22]; lipid peroxidation and abnormal iron metabolism cannot be observed in other forms of cell death. GPX4 is the core element of ferroptosis execution and controls the balance of the cellular redox state. The study of ferroptosis is still in the early stage and there are many unanswered questions, such as the exact function of iron in ferroptosis, or the mechanism by which lipid ROS induce ferroptosis. Furthermore, it is still possible more signaling pathways may be involved in ferroptosis.
Cardiomyocyte loss results in dramatic damages to cardiac function and ultimately in heart failure, after which adult cardiomyocytes are unable to regenerate. Therefore, preventing and reducing myocardial cell death is key to improving and restoring cardiac function in cardiovascular diseases. However, this phenomenon was only just discovered in relation to cardiovascular diseases; thus, further studies need to focus on the mechanism of ferroptosis in the development and staging of cardiovascular diseases to help developing precise treatments. Moreover, ferroptosis plays a role in the evolution of cancer, neurotoxicity, and liver and kidney diseases [26, 42, 86-88]. Finally, artemisinin, baicalin, and puerarin inhibit ferroptosis; however, the underlying mechanism is still unclear. In conclusion, ferroptosis, a recently described type of cell death, plays an important role in cardiovascular diseases, but its mechanism needs to be further explored; intervention measures that target ferroptosis may be the basis for new therapeutic strategies for many diseases, including cardiovascular diseases.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81770275), the Key Research and Development Project of Shandong Province (2017 GSF18127), and the Taishan Scholar Program of Shandong Province.

Competing Interests

The authors declare no competing interests.

References

[1] Yang WS, SrIRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell, 156:317-331.
[2] Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. (2017). Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell, 171:273-285.
[3] Stewart J, Mannathan G, Wilkinson P (2017). Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc Dis, 6:2048004016687211.
[4] Mendis S, Davis S, Norrving B (2015). Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke, 46:e121-122.
[5] Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130:432-437.
[6] Yonezawa M, Back SA, Gan X, Rosenberg PA, Volpe JJ (1996). Cystine deprivation induces oligodendrogial death: rescue by free radical scavengers and by a diffusible glial factor. J Neurochem, 67:566-573.
[7] Wang H, Li J, Follett PL, Zhang Y, Cotanha DA, Jensen FE, et al. (2004). 12-Lipoxygenase plays a key role in cell death caused by glutathione depletion and arachidonic acid in rat oligodendrocytes. Eur J Neurosci, 20:2049-2058.
[8] Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989). Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron, 2:1547-1558.
[9] Dolma S, Lessnick SL, Hahn WC, Stockwell BR (2003). Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 3:285-296.
[10] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149:1060-1072.
[11] Yang WS, Stockwell BR (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol, 15:234-245.
[12] Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. (2016). Ferroptosis: process and function. Cell Death and Differentiation, 23:369-379.
[13] Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. (2014). Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol, 16:1180-1191.
[14] Gong YN, Guy C, Olauzon H, Becker JU, Yang M, Fitzgerald P, et al. (2017). ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences. Cell, 169:286-300 e216.
[15] Parzych KR, Klionsky DJ (2014). An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal, 20:460-473.
[16] He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. (2009). Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell, 137:1100-1111.
[17] Fuchs Y, Steller H (2011). Programmed cell death in animal development and disease. Cell, 147:742-758.
[18] Zhou W, Yuan J (2014). SnapShot: Necroptosis. Cell, 158:464-464 e461.
[19] Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, et al. (2014). Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell, 54:133-146.
[20] Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, et al. (2007). Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell, 128:931-946.
[21] Yang WS, Stockwell BR (2016). Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol, 26:165-176.
[22] Doll S, Conrad M (2017). Iron and ferroptosis: A still ill-defined liaison. IUBMB Life, 69:423-434.
Ma S, Henson EE, Chen Y, Gibson SB (2016). Ferroptosis is induced following siramesine and latapinib treatment of breast cancer cells. Cell Death & Disease, 7.

Hao SH, Liang BS, Huang Q, Dong SM, Wu ZZ, He WM, et al. (2018). Metabolic networks in ferroptosis. Oncology Letters, 15:5405-5411.

Gao M, Monian P, Quadri N, Ramasamy R, Jiang X (2015). Glutaminolysis and Transferrin Regulate Ferroptosis. Mol Cell, 59:298-308.

Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. (2019). Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A, 116:2672-2680.

Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X, et al. (2015). HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene, 34:5617-5625.

Wang H, An P, Xie E, Wu Q, Fang X, Gao H, et al. (2017). Characterization of ferroptosis in murine models of hemochromatosis. Hepatology, 66:449-465.

Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X (2016). Ferroptosis is an autophagic cell death process. Cell Res, 26:1021-1032.

Mancias JD, Ontaño Vaitez L, Nissim S, Biancur DE, Kim AJ, Wang X, et al. (2015). Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife, 4.

Quiles Del Rey M, Mancias JD (2019). NCOA4-Mediated Ferritinophagy: A Potential Link to Neurodegeneration. Front Neurosci, 13:238.

Latunde-Dada GO (2017). Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta Gen Subj, 1861:1893-1900.

Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, et al. (2007). RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature, 447:864-868.

Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB, et al. (2019). Role of Mitochondria in Ferroptosis. Mol Cell, 73:354-363 e353.

Lambeth JD (2007). Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med, 43:332-347.

Laleu B, Gaggi C, Orchard M, Fioraso-Luce C, Cagnon L, Honnegrinou-Molango S, et al. (2010). First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem, 53:7715-7730.

Dell S, Proneth B, Tyurina YY, Panzulli E, Kobayashi S, Ingold I, et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol, 13:91-98.

Dickson SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, et al. (2015). Human Haploid Cell Genomics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol, 10:1604-1609.

Shah R, Shchepinov MS, Pratt DA (2018). Resolving the Role of Lipoygenases in the Initiation and Execution of Ferroptosis. ACS Cent Sci, 4:387-396.

Maldonado EN, Sheldon KL, DeHart DN, Patnaik J, Manevich Y, Townsends D, et al. (2013). Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin. J Biol Chem, 288:11920-11929.

Vigil D, Cheriflis J, Rossman KL, Der CJ (2010). Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer, 10:842-857.

Linkermann A, Skoula R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, et al. (2014). Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A, 111:16836-16841.

Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, Kopf M (2015). T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J Exp Med, 212:555-568.

Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. (2015). Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 520:57-62.

Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). p53 mutations in human cancers. Science, 253:49-53.

Kamat T (2009). Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci, 100:1382-1388.

Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR (2016). Loss of cysteinyI-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ, 23:270-278.

Gao H, Bai Y, Jia Y, Zhao Y, Kang R, Tang D, et al. (2018). Ferroptosis is a lysosomal cell death process. Biochem Biophys Res Commun, 503:1550-1556.

Yeung K, Setz T, Li S, Janosch P, McFerran B, Kaiser C, et al. (1999). Suppression of Raf-1 kinase activity and MAP kinase signalling by RRIP. Nature, 401:173-177.

Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al. (2017). PEBP1 Wardens Ferroptosis by Enabling Lipoygenase Generation of Lipid Death Signals. Cell, 171:628-641 e626.

Fanelus I, Desrosiers RR (2008). Reactive oxygen species generated by thiol modulating phenylarsine oxide stimulate the expression of protein L-isoaaspartyl methyltransferase. Biochem Biophys Res Commun, 371:203-208.

Had-Aissouni L (2012). Maintenance of antioxidant defenses of brain cells: plasma membrane glutamate transporters and beyond. Amino Acids, 42:159-161.

Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. (2016). Activation of the p62 Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology, 63:173-184.

Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. (2019). FSP1 is a glutathione-
Targeting ferroptosis to treat cardiovascular diseases

Jie J., et al.

independent ferroptosis suppressor. Nature.

[55] Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang PH, et al. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature.

Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, et al. (2015). Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell, 27:211-222.

[57] Shaw AT, Winslow MM, Magendanz M, Ouyang C, Dowdle J, Subramanian A, et al. (2011). Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A, 108:8773-8778.

Sehm T, Fan Z, Ghiochiani A, Rauh M, Engelhorn T, Minakaki G, et al. (2016). Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. Oncotarget, 7:36021-36033.

[59] Zhang L, Gong F, Zhang F, Ma J, Zhang P, Shen J (2013). Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int J Nanomedicine, 8:1517-1524.

Lachaiere E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, et al. (2014). Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res, 34:6417-6422.

Ooko E, Saeed ME, Kadioglu O, Saeed ME, Kadioglu O, Sarvi S, Colak M, Elmastsoy K, et al. (2015). Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine, 22:1045-1054.

Boonnomp P, Karttunen M, Wong-Ekkabut J (2017). Alpha-tocopherol inhibits pore formation in oxidized bilayers. Phys Chem Chem Phys, 19:5699-5704.

Zilka O, Shah R, Li B, Friedmann Angeli JP, Griesser M, Conrad M, et al. (2017). On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptic Cell Death. ACS Cent Sci, 3:232-243.

Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, et al. (2014). Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc, 136:4551-4556.

Krainz T, Gaschler MM, Lim C, Sacher JR, Stockwell BR, Wipf P (2016). A Mitochondrial-Targeted Nitroxide Is a Potent Inhibitor of Ferroptosis. ACS Cent Sci, 2:653-659.

Yin H, Xu L, Porter NA (2011). Free radical lipid peroxidation: mechanisms and analysis. Chem Rev, 111:5944-5972.

Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. (2017). Oxidized arachidonic and ardenic PEs navigate cells to ferroptosis. Nat Chem Biol, 13:81-90.

Liu Y, Wang W, Li Y, Xiao Y, Cheng J, Jia J (2015). The 5-Lipoxygenase Inhibitor Zileuton Confers Neuroprotection against Glutamate Oxidative Damage by Inhibiting Ferroptosis. Biol Pharm Bull, 38:1234-1239.

Zhang Y, Sun C, Zhao C, Hao J, Zhang Y, Fan B, et al. (2019). Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. Brain Res, 1706:48-57.

Zhang F, Tao Y, Zhang Z, Guo X, An P, Shen Y, et al. (2012). Metallooxidase Steap3 coordinates the regulation of iron homeostasis and inflammatory responses. Haematologica, 97:1826-1835.

Yazdani M (2015). Concerns in the application of fluorescent probes DCDHF-DA, DHR 123 and DHE to measure reactive oxygen species in vitro. Toxicol In Vitro, 30:578-582.

Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE (2004). Prouinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes, 53:2079-2086.

Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, 3rd, et al. (2016). Autophagy promotes ferroptosis by degradation of ferritin. Autophagy, 12:1425-1428.

Houessinon A, Francois C, Sauzay C, Louandre C, Mongelard G, Godin C, et al. (2016). Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. Mol Cancer, 15:38.

Guo Z, Ran Q, Roberts LJ, 2nd, Zhou L, Richardson A, Sharan C, et al. (2008). Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med, 44:343-352.

Wortmann M, Schneider M, Pircher J, Helffritsch J, Aicher M, Veci N, et al. (2013). Combined deficiency in glutathione peroxidase 4 and vitamin E causes multiorgan thrombus formation and early death in mice. Circ Res, 113:408-417.

Glynn RJ, Ridker PM, Goldhaber SZ, Zee RY, Buring JE (2007). Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation, 116:1497-1503.

Baba Y, Higa JK, Shimada BK, Horiuichi KM, Suhara T, Kobayashi M, et al. (2018). Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol, 314:H659-H668.

Kreisel D, Sugimoto S, Tietjen S, Zhu J, Yamamoto S, Krupnick AS, et al. (2011). Selective supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation, 116:1497-1503.

Li W, Feng G, Gauthier JM, Lokshina I, Higashikubo R, Evans S, et al. (2019). Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. J Clin Invest, 129:2293-2304.

Miller PE, van Diepen S, Ahmad T (2019). Acute Decompensated Heart Failure Complicated by Respiratory Failure. Circ Heart Fail, 12:e00613.

Liu B, Zhao C, Li H, Chen X, Ding Y, Xu S (2018).
| Reference | Title \& Authors | Journal | Page(s) |
|-----------|------------------|---------|---------|
| [83]      | Conrad M, Proneth B (2019). Broken hearts: Iron overload, ferroptosis and cardiomyopathy. | Cell Res, 29:263-264. |         |
| [84]      | Berdoukas V, Coates TD, Cabantchik ZI (2015). Iron and oxidative stress in cardiomyopathy in thalassemia. | Free Radic Biol Med, 88:3-9. |         |
| [85]      | Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Porreca E (2018). Iron status and oxidative stress in the aged rabbit heart. | J Mol Cell Cardiol, 114:328-333. |         |
| [86]      | Sundstrom L, Morrison B, 3rd, Bradley M, Pringle A (2005). Organotypic cultures as tools for functional screening in the CNS. | Drug Discov Today, 10:993-1000. |         |
| [87]      | Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, et al. (2019). CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. | Nature, 569:270-274. |         |
| [88]      | Lorincz T, Jennitz K, Kardon T, Mandl J, Szarka A (2015). Ferroptosis is Involved in Acetaminophen Induced Cell Death. | Pathol Oncol Res, 21:1115-1121. |         |